33 research outputs found

    Metacognitive functioning predicts positive and negative symptoms over 12 months in first episode psychosis

    Get PDF
    The negative symptoms of schizophrenia are a major source of impairment and distress but both pharmacological and psychological treatment options provide only modest benefit. Developing more effective psychological treatments for negative symptoms will require a more sophisticated understanding of the psychological processes that are implicated in their development and maintenance. We extended previous work by demonstrating that metacognitive functioning is related to negative symptom expression across the first 12 months of first episode psychosis (FEP). Previous studies in this area have either been cross-sectional or have used much older participants with long-standing symptoms. In this study, forty-five FEP participants were assessed three times over 12 months and provided data on PANSS rated symptoms, premorbid adjustment, metacognitive functioning, and DUP. Step-wise linear regression showed that adding metacognition scores to known predictors of negative symptoms (baseline symptom severity, gender, DUP, and premorbid academic and social adjustment) accounted for 62% of the variance in PANSS negative symptom scores at six months and 38% at 12 months. The same predictors also explained 47% of the variance in positive symptoms at both six and 12 months. However, exploration of the simple correlations between PANSS symptom scores and metacognition suggests a stronger univariate relationship between metacognition and negative symptoms. Overall, the results indicate that problems with mental state processing may be important determinants of negative symptom expression from the very early stages of psychosis. These results provide further evidence that metacognitive functioning is a potentially relevant target for psychological interventions

    La CIM et le DSM ou l'impossible validation: pourquoi le ver est dans le fruit

    No full text
    International audienceLes classifications internationales en psychiatrie, la CIM et le DSM, ont permis un accroissement rapide des connaissances factuelles sur les troubles qu'elles dĂ©finissent, sans que cela se soit accompagnĂ© d'un accroissement de leur validitĂ©. La notion de validitĂ© n'est applicable qu'aux classifications scientifiques. Celles-ci cherchent Ă  modĂ©liser la rĂ©alitĂ© de phĂ©nomĂšnes naturels. Ce qui est validable dans une classification scientifique, c'est ce modĂšle. En mĂ©decine, une maladie correspond Ă  un modĂšle Ă©tio-physiopathologique de la dĂ©viation morbide d'un processus naturel. Or, la CIM et le DSM Ă©tant athĂ©oriques, ils ne reposent sur aucun modĂšle et sont donc invalidables. Ainsi, l'utilitĂ© de ces classifications doit ĂȘtre limitĂ©e Ă  la pratique technique. À vouloir les appliquer en science, ces instruments ne peuvent que ralentir toute avancĂ©e basĂ©e sur la mĂ©thode classique des corrĂ©lations cliniques

    Confirmation of TFAP2A gene involvement in branchio-oculo-facial syndrome (BOFS) and report of temporal bone anomalies.

    No full text
    International audienceBranchio-oculo-facial syndrome (BOFS) is an autosomal-dominant condition characterized by three main features, respectively: branchial defects, ocular anomalies, and craniofacial defects including cleft lip and/or palate (CL/P). We report on one family with three affected, and two sporadic cases that have been found to carry missense mutations in the newly reported BOFS gene: TFAP2A. This report confirms the involvement of this transcription factor in this developmental syndrome with clinical variability. Moreover, we present CT scan temporal bone anomalies in the familial cases, related to branchial arch defects, highlighting the importance of radiological investigations for differential diagnosis

    The Renpenning syndrome spectrum: new clinical insights supported by 13 new PQBP1-mutated males.

    No full text
    International audienceSince the first reports of polyglutamine-binding protein 1 (PQBP1) mutations in Renpenning syndrome and related disorders, the spectrum of PQBP1-linked clinical manifestations has been outlined from rare published case reports. The phenotypic description is often obtained from medical archives, and therefore, heterogeneous. Moreover, some aspects such as brain imaging or cognitive and behavioral functioning are rarely described. In this study, 13 PQBP1-mutated French patients were subjected to a standardized clinical, cognitive and behavioral assessment. Physical measurements of their relatives were also collected. We report on a recognizable clinical and radiological phenotype. All patients presented with microcephaly, leanness and mild short stature, relative to familial measurements. Three new clinical features are described: upper back progressive muscular atrophy, metacarpophalangeal ankylosis of the thumb and velar dysfunction. The specific facial dysmorphic features included at least four of the following signs: long triangular face, large ridged nose, half-depilated eyebrows, dysplastic or protruding ears and rough slightly sparse hair. An over-aged appearance was noticed in elderly patients. Cortical gyrification was normal based on available magnetic brain imaging of six patients. PQBP1-linked microcephaly (or Renpenning syndrome) is an X-linked mental retardation syndrome, which has clinically recognizable features
    corecore